Dulin Wang
YOU?
Author Swipe
View article: A medically grounded LLM agent–based tool to detect patient safety events in medical records
A medically grounded LLM agent–based tool to detect patient safety events in medical records Open
Large language models (LLMs) have shown incredible promise in medicine. While LLMs may be particularly useful in areas requiring extensive review of clinical records, their use remains limited due to their tendency to hallucinate and fabri…
Rapid Progressors in Alzheimer's Disease: Implications for Symptomatic Clinical Trial Design Open
Background Previous clinical trials for Alzheimer's disease (AD) have identified different progression patterns among patients: some showing minimal cognitive change (slow progressors, SPs) and others experiencing rapid decline (rapid prog…
View article: Deep learning to predict rapid progression of Alzheimer’s disease from pooled clinical trials: A retrospective study
Deep learning to predict rapid progression of Alzheimer’s disease from pooled clinical trials: A retrospective study Open
The rate of progression of Alzheimer’s disease (AD) differs dramatically between patients. Identifying the most is critical because when their numbers differ between treated and control groups, it distorts the outcome, making it impossible…
Characterizing Treatment Non-responders and Responders in Completed Alzheimer's Disease Clinical Trials. Open
Characterizing differential responses to Alzheimer's disease (AD) drugs will provide better insights into personalized treatment strategies. Our study aims to identify heterogeneous treatment effects and pre-treatment features that moderat…
Characterizing Treatment Non-responders vs. Responders in Completed Alzheimer’s Disease Clinical Trials Open
Alzheimer’s disease (AD) patients have varying responses to AD drugs and there may be no single treatment for all AD patients. Trial after trial shows that identifying non-responsive and responsive subgroups and their corresponding moderat…
Knowledge-guided Deep Temporal Clustering for Alzheimer’s Disease Subtypes in Completed Clinical Trials Open
Alzheimer’s disease (AD) is a multifaceted neurodegenerative disorder with varied patient progression. We aim to test the hypothesis that AD patients can be categorized into subgroups based on differences in progression. We leveraged data …